Efficacy and safety of intraperitoneal bevacizumab combined with hyperthermic intraperitoneal chemotherapy in the treatment of patients with ovarian cancer and peritoneal effusion and the effect on serum lncRNA H19 and VEGF levels

References

• Ba, M., et al., 2016. Hyperthermic intraperitoneal perfusion chemotherapy and cytoreductive surgery for controlling malignant ascites from ovarian cancer. International Journal of Gynecologic Cancer, 26 (9), 1571–1579.
   PubMed Web of Science ®Google Scholar
• Bizzarri, N., et al., 2021. Is there any therapeutic role of pelvic and para-aortic lymphadenectomy in apparent early stage epithelial ovarian cancer? Gynecologic Oncology, 160 (1), 56–63.
   PubMed Web of Science ®Google Scholar
• Bogani, G., et al., 2020. Immunotherapy for platinum-resistant ovarian cancer. Gynecologic Oncology, 158 (2), 484–488.
   Google Scholar
• Chen, Y., et al., 2018. VEGF and SEMA4D have synergistic effects on the promotion of angiogenesis in epithelial ovarian cancer. Cellular & Molecular Biology Letters, 23 (1), 2.
   Google Scholar
• Cui, S., et al., 2012. B ultrasound-guided hyperthermic intraperitoneal perfusion chemotherapy for the treatment of malignant ascites. Oncology Reports, 28 (4), 1325–1331.
   Google Scholar
• Dalal, V., et al., 2018. Biomarker potential of IL-6 and VEGF-A in ascitic fluid of epithelial ovarian cancer patients. Clinica Chimica Acta, 482, 27–32.
   Google Scholar
• Di Donato, V., et al., 2017. Trends in mortality after primary cytoreductive surgery for ovarian cancer: a systematic review and metaregression of randomized clinical trials and observational studies. Annals of Surgical Oncology, 24 (6), 1688–1697.
   PubMed Web of Science ®Google Scholar
• Fagotti, A., et al., 2020. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). International Journal of Gynecologic Cancer, 30 (11), 1657–1664.
   PubMed Web of Science ®Google Scholar
• Farrell, R. and Burling, M., 2021. HIPEC: Turning up the heat on ovarian cancer. Australian and New Zealand Journal of Obstetrics and Gynaecology, 61 (1), 11–15.
   PubMed Web of Science ®Google Scholar
• Ford, C. E., et al., 2020. The untapped potential of ascites in ovarian cancer research and treatment. British Journal of Cancer, 123 (1), 9–16.
   PubMed Web of Science ®Google Scholar
• Gadducci, A., Cosio, S. and Lippolis, P. V., 2022. Hyperthermic intraperitoneal chemotherapy in the management of primary epithelial ovarian cancer: a debated issue for gynecologic oncologists. Anticancer Research, 42 (10), 4659–4665.
   PubMed Web of Science ®Google Scholar
• Geindreau, M., Ghiringhelli, F. and Bruchard, M., 2021. Vascular endothelial growth factor, a key modulator of the anti-tumor immune response. International Journal of Molecular Sciences, 22 (9), 4871.
   PubMed Web of Science ®Google Scholar
• Ghoneum, A., et al., 2021. Exploring the clinical value of tumor microenvironment in platinum-resistant ovarian cancer. Seminars in Cancer Biology, 77, 83–98.
   Google Scholar
• Gupta, K. K., Gupta, V. K. and Naumann, R. W., 2019. Ovarian cancer: screening and future directions. International Journal of Gynecologic Cancer, 29 (1), 195–200.
   PubMed Web of Science ®Google Scholar
• Haunschild, C. E. and Tewari, K. S., 2020. Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer. Future Oncology, 16 (7), 225–246.
   PubMed Web of Science ®Google Scholar
• He, L., et al., 2019. Ovarian cancer cell-secreted exosomal miR-205 promotes metastasis by inducing angiogenesis. Theranostics, 9 (26), 8206–8220.
   PubMed Web of Science ®Google Scholar
• Jackson, A. L., Eisenhauer, E. L. and Herzog, T. J., 2015. Emerging therapies: angiogenesis inhibitors for ovarian cancer. Expert Opinion on Emerging Drugs, 20 (2), 331–346.
   PubMed Web of Science ®Google Scholar
• Jiang, Y., Wang, C. and Zhou, S., 2020. Targeting tumor microenvironment in ovarian cancer: Premise and promise. Biochimica et Biophysica Acta, Reviews on Cancer, 1873 (2), 188361.
   PubMed Web of Science ®Google Scholar
• Khaloo, P., et al., 2020. Nitric oxide and TNF-alpha are correlates of diabetic retinopathy independent of hs-CRP and HbA1c. Endocrine, 69 (3), 536–541.
   PubMed Web of Science ®Google Scholar
• Lagana, A. S., et al., 2015. Cytogenetic analysis of epithelial ovarian cancer’s stem cells: an overview on new diagnostic and therapeutic perspectives. European Journal of Gynaecological Oncology, 36 (5), 495–505.
   PubMed Web of Science ®Google Scholar
• Lemoine, L., Sugarbaker, P. and Van der Speeten, K., 2017. Drugs, doses, and durations of intraperitoneal chemotherapy: standardising HIPEC and EPIC for colorectal, appendiceal, gastric, ovarian peritoneal surface malignancies and peritoneal mesothelioma. International Journal of Hyperthermia, 33 (5), 582–592.
   Google Scholar
• Li, J., et al., 2021. Bevacizumab confers significant improvements in survival for ovarian cancer patients with low miR-25 expression and high miR-142 expression. Journal of Ovarian Research, 14 (1), 166.
   Web of Science ®Google Scholar
• Lim, M. C., Collaborators, H. f. O. C., et al., 2022. Survival after hyperthermic intraperitoneal chemotherapy and primary or interval cytoreductive surgery in ovarian cancer: a randomized clinical trial. The Journal of the American Medical Association Surgery, 157 (5), 374.
   PubMed Web of Science ®Google Scholar
• Ma, C., 2022. Effect of bevacizumab combined with chemotherapy on SDF-1 and CXCR4 in epithelial ovarian cancer and its prognosis. World Journal of Surgical Oncology, 20 (1), 154.
   Web of Science ®Google Scholar
• Ma, H., et al., 2022. Long non-coding RNA H19 correlates with unfavorable prognosis and promotes cell migration and invasion in ovarian cancer. Ginekologia Polska, 93 (1), 1–6.
   Web of Science ®Google Scholar
• Malayev, Y., Levene, R. and Gonzalez, F., 2012. Palliative chemotherapy for malignant ascites secondary to ovarian cancer. American Journal of Hospice and Palliative Medicine®, 29 (7), 515–521.
   PubMed Web of Science ®Google Scholar
• Mamguem K., A., et al., 2021. Long-term quality of life and sexual function of elderly people with endometrial or ovarian cancer. Health and Quality of Life Outcomes, 19 (1), 56.
   Web of Science ®Google Scholar
• Mao, C. L., Seow, K. M. and Chen, K. H., 2022. The utilization of bevacizumab in patients with advanced ovarian cancer: a systematic review of the mechanisms and effects. International Journal of Molecular Sciences, 23 (13), 6911.
   Google Scholar
• Moufarrij, S., et al., 2019. Epigenetic therapy for ovarian cancer: promise and progress. Clinical Epigenetics, 11 (1), 7.
   PubMedGoogle Scholar
• Musella, A., et al., 2015. PARP inhibition: A promising therapeutic target in ovarian cancer. Cellular and Molecular Biology, 61 (6), 44–61.
   PubMed Web of Science ®Google Scholar
• Musella, A., et al., 2017. Bevacizumab in ovarian cancer: state of the art and unanswered questions. Chemotherapy, 62 (2), 111–120.
   PubMed Web of Science ®Google Scholar
• Onuma, T., et al., 2021. Copper content in ascitic fluid is associated with angiogenesis and progression in ovarian cancer. Journal of Trace Elements in Medicine and Biology, 68, 126865.
   PubMed Web of Science ®Google Scholar
• Pascual-Anton, L., et al., 2021. Mesothelial-to-mesenchymal transition and exosomes in peritoneal metastasis of ovarian cancer. International Journal of Molecular Sciences, 22 (21), 11496.
   Google Scholar
• Rickard, B. P., et al., 2021. Malignant ascites in ovarian cancer: cellular, acellular, and biophysical determinants of molecular characteristics and therapy response. Cancers, 13 (17), 4318.
   PubMed Web of Science ®Google Scholar
• Rodrigues, I. S. S., et al., 2020. IL-6 and IL-8 as prognostic factors in peritoneal fluid of ovarian cancer. Immunological Investigations, 49 (5), 510–521.
   PubMed Web of Science ®Google Scholar
• Schmittgen, T. D. and Livak, K. J., 2008. Analyzing real-time PCR data by the comparative C(T) method. Nature Protocols, 3 (6), 1101–1108.
   PubMed Web of Science ®Google Scholar
• Shi, J., et al., 2021. Circulating long noncoding RNA, GAS5, as a novel biomarker for patients with atrial fibrillation. Journal of Clinical Laboratory Analysis, 35 (1), e23572.
   Web of Science ®Google Scholar
• Shimizu, Y., et al., 2019. The usefulness of bevacizumab for relief from symptomatic malignant ascites in patients with heavily treated recurrent ovarian cancer. Journal of Obstetrics and Gynaecology Research, 45 (12), 2435–2439.
   PubMed Web of Science ®Google Scholar
• Sjoquist, K. M., et al., 2021. REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer. Gynecology Oncology, 161 (2), 374–381.
   Google Scholar
• Smolle, E., Taucher, V. and Haybaeck, J., 2014. Malignant ascites in ovarian cancer and the role of targeted therapeutics. Anticancer Research, 34 (4), 1553–1561.
   Google Scholar
• Sung, H., et al., 2021. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71 (3), 209–249.
   PubMed Web of Science ®Google Scholar
• Tian, X., et al., 2021. LncRNA-H19 regulates chemoresistance to carboplatin in epithelial ovarian cancer through microRNA-29b-3p and STAT3. Journal of Cancer, 12 (19), 5712–5722.
   PubMed Web of Science ®Google Scholar
• Tsikouras, P., et al., 2013. The contribution of catumaxomab in the treatment of malignant ascites in patients with ovarian cancer: a review of the literature. Archives of Gynecology and Obstetrics, 288 (3), 581–585.
   PubMed Web of Science ®Google Scholar
• van Driel, W. J., et al., 2018. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. The New England Journal of Medicine, 378 (3), 230–240.
   PubMed Web of Science ®Google Scholar
• Vitale, S. G., et al., 2019. Management of endometrial, ovarian and cervical cancer in the elderly: current approach to a challenging condition. Archives of Gynecology and Obstetrics, 299 (2), 299–315.
   PubMed Web of Science ®Google Scholar
• Wang, H., et al., 2014. The expression of VEGF and Dll4/Notch pathway molecules in ovarian cancer. Clinica Chimica Acta, 436, 243–248.
   Web of Science ®Google Scholar
• Wang, J. Y., Lu, A. Q. and Chen, L. J., 2019. LncRNAs in ovarian cancer. Clinica Chimica Acta. 490, 17–27.
   Web of Science ®Google Scholar
• Wang, Y. and Gao, W. J., 2021. Long non-coding RNA-H19 promotes ovarian cancer cell proliferation and migration via the microRNA-140/Wnt1 axis. The Kaohsiung Journal of Medical Sciences, 37 (9), 768–775.
   PubMed Web of Science ®Google Scholar
• Wimberger, P., et al., 2022. Bevacizumab may differentially improve prognosis of advanced ovarian cancer patients with low expression of VEGF-A165b, an antiangiogenic VEGF-a splice variant. Clinica Cancer Research, 28 (21), 4660–4668.
   PubMed Web of Science ®Google Scholar
• Xu, H., Ding, Y. and Yang, X., 2021. Overexpression of long noncoding RNA H19 downregulates miR-140-5p and activates PI3K/AKT signaling pathway to promote invasion, migration and epithelial-mesenchymal transition of ovarian cancer cells. BioMed Research International, 2021, 6619730.
   PubMed Web of Science ®Google Scholar
• Zhang, T., et al., 2016. Docetaxel combined with intraperitoneal hyperthermic perfusion chemotherapy and hyperthermia in the treatment of advanced ovarian cancer. Oncol Letters, 11 (5), 3287–3292.
   PubMed Web of Science ®Google Scholar
• Zhang, Y. and Brekken, R. A., 2022. Direct and indirect regulation of the tumor immune microenvironment by VEGF. Journal of Leukocyte Biology, 111 (6), 1269–1286.
   PubMed Web of Science ®Google Scholar
• Zhao, H., et al., 2015. Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a phase III clinical trial. Medical Oncology, 32 (2), 292.
   PubMed Web of Science ®Google Scholar
• Zhao, L., et al., 2021. Ginsenoside Rg3 suppresses ovarian cancer cell proliferation and invasion by inhibiting the expression of lncRNA H19. Acta Biochimica Polonica, 68 (4), 575–582.
   PubMed Web of Science ®Google Scholar